Purpose The aim of this study was to test the safety, tolerability and efficacy of a novel combination of an anabolic β 2 -agonist and an appetite stimulant in patients with cancer cachexia. Methods Thirteen patients (M/F 5:8) with advanced malignancy and involuntary weight loss received oral formoterol (80 μg/day) and megestrol acetate (480 mg/day) for up to 8 weeks. Quadriceps size (MRI), quadriceps and hand-grip strength, lower limb extensor power, physical activity and quality of life were measured at baseline and at 8 weeks.
Introduction
Cancer cachexia has recently been defined as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) [1] . Cancer patients become cachectic as a result of reduced food intake (secondary to anorexia), abnormal metabolism or most commonly, a variable combination of the two. In treating the anorexia component of cancer cachexia, it is possible to use nutritional counselling/supplements or a pharmacological approach. At present, two classes of drug are used off-label: progestins and corticosteroids. Neither provides optimal control as they lead mainly to temporary increases in body fat and water, rather than adding to the key component, muscle mass. Indeed, corticosteroids may induce muscle wasting. The progestin megestrol acetate is the most widely used drug but is approved only for aids-related cachexia in the USA and cancer cachexia only in Italy and Spain. It is a potent appetite stimulant as well as enhancing physical performance and muscle force in tumour bearing rats [2] . In a large meta-analysis, megestrol was shown to improve appetite and weight but had no benefit in terms of quality of life or survival [3] . The dose of 480 mg/day has been widely studied in cancer cachexia and is generally believed to be an appropriate dose, in terms of efficacy and safety [4, 5] .
In relation to key metabolic aspects of cachexia, β 2 -agonists offer strong potential to reverse muscle atrophy. Formoterol fumarate is a long-acting β 2 -agonist, widely used for more than 20 years as a therapy for asthma and chronic obstructive pulmonary disease. Although formoterol has not previously been studied clinically as a treatment for muscle wasting, there is evidence that other β 2 -agonists, such as albuterol (salbutamol) and clenbuterol, can arrest muscle atrophy and increase muscle mass and strength in conditions such as Becker and Duchenne muscular dystrophies and after orthopaedic surgery [6, 7] , as well as in healthy volunteers [8] . However, widespread clinical use of such β 2 -agonists has been limited due to relative lack of selectivity for skeletal over cardiac muscle, leading to cardiovascular side effects. Formoterol is a particularly promising β 2 -agonist due to a high degree of selectivity for skeletal muscle β 2 -receptors, favourable efficacy/toxicity ratio and proven clinical tolerability by the oral route of administration. Formoterol, like other β 2 -agonists, has marked anti-catabolic and anabolic effects, mediated through at least two pathways: inhibition of the ATP-dependent ubiquitin-proteasome pathway, leading to reduced proteolysis, and inhibition of caspase-mediated apoptosis. Formoterol also appears to stimulate satellite cells directly to regenerate muscle fibres [9] . β 2 -agonists have also been shown to reduce production of TNFα and IFNγ in experimental systems [10, 11] . Formoterol has shown promising influence on muscle mass in animal models, of cancer cachexia. Using the rat Yoshida AH-130 ascites hepatoma and mouse Lewis lung tumour models, formoterol at 2 mg/kg intra-peritoneally resulted in highly significant increases in the mass of skeletal muscles such as gastrocnemius and soleus, as well as adipose tissues, compared with vehicle-treated animals [12] . In normal rats, doses of formoterol as low as 1 mg/kg/day elicited significant muscle hypertrophy with minimal cardiac hypertrophy [13] .
This single-arm pilot study examined the safety and tolerability of megestrol combined with formoterol in cachectic cancer patients and to evaluate the potential of the combination to halt or reverse the muscle wasting seen in cachexia.
Methods

Overview
This was a single centre, uncontrolled, exploratory study, assessing a fixed dose of formoterol fumarate and megestrol acetate given concomitantly to adult patients with advanced cancer and cachexia. The protocol received research ethics committee approval. Written informed consent was obtained from all patients. All procedures were in accordance with International Conference on Harmonization guidelines on Good Clinical Practise and the Helsinki Declaration.
Objectives
The primary objective was to assess the efficacy of formoterol and megestrol in combination in cancer cachexia. The primary efficacy endpoint was muscle response (see below). Secondary efficacy endpoints included quantitative changes in body weight, physical activity and quality of life. The secondary objective was assessment of the safety and tolerability of the combination therapy.
Protocol
Patients were screened for eligibility (ESM 1) during the 14 days prior to trial entry. The diagnostic criterion for cachexia was weight loss ≥2 % in the preceding 2 months or ≥5 % in the preceding 6 months compared with pre-illness stable weight. Patients were admitted to the clinical research facility on day 1 and discharged 6 h after the first dose of study drugs. Safety assessments included physical examination, monitoring of vital signs, clinical laboratory tests and EKG. Patients were contacted at home by telephone after 24 h to assess any emergent toxicity. Further safety assessments were conducted at 2, 4, 6, 8 and 12 weeks. Measurements of muscle size, strength and power output, total body weight, quality of life and physical activity were conducted at baseline and at 8 weeks.
Patients were requested to take formoterol 1×40 μg and megestrol 2×160 mg tablets each morning and formoterol 1× 40 μg and megestrol 1×160 mg tablet each evening, for a period of 8 weeks. Patients surviving beyond 8 weeks were offered the combination when requested on compassionate grounds. Self-reported tablet intake and a tablet count on return of medications were used to determine patient compliance.
Adverse events
Intensity of AEs was graded in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (http://safetyprofiler-ctep.nci.nih.gov/ CTC/CTC.aspx) and the relationship to study drug was also assessed.
Sample size calculation A sample size of 13 patients was sufficient to give an 80 % power of rejecting a reference proportion of muscle responders of 10 % with an exact 5 % one-sided test when the true proportion of muscle responders would be at the clinically relevant value of 40 %. If the lower bound of the 90 % confidence interval of the proportion of muscle responders were wholly above the reference proportion, then the null hypothesis (that the true proportion of muscle responders is equal to or less than 10 %) would be rejected at a one-sided significance level of 5 %. This would be the case if four or more patients were muscle responders.
Muscle response
Protocol-defined response criteria are given in Table 1 . An overall major response was documented if achieved in either domain of muscle size or muscle function (quadriceps strength and power), for either the left or right side of the body.
Physical assessments
Anthropometry: Body weight was measured using a beam scale (Seca, Birmingham, UK) and height using a standard wall mounted measure. Muscle function: Maximum voluntary isometric knee extensor strength (IKES), lower limb extensor power (LLEP) and maximum handgrip strength (HGS) were measured using dynamometry. Muscle cross-sectional area (CSA ) and volume : These outcomes of muscle size were measured using magnetic resonance imaging (MRI). T1-weighted axial images (Philips Gyroscan 1.5-T) were prescribed from the proximal border of the patella to the anterior iliac spine using a previously described protocol [14] . The cross-sectional area (in square millimetres) of the quadriceps muscle in each image was quantified off-line using ANALYZE 8.0 (Mayo Clinic, Rochester, USA). CSA for each slice area was multiplied by slice thickness and slice volumes summed to give quadriceps volume. Muscle Quality: MRIderived muscle mid-femur CSA was combined with the functional measurements to give a measure of muscle mechanical quality (muscle quality=IKES ÷ CSA (in Newton per square millimetre)). Physical activity : This was monitored directly for at least three consecutive days at the beginning and again at the end of treatment using accelerometry (PAL Technologies Ltd., Glasgow, UK). Activity was quantified as average daily step count (steps/24 h). Quality of life and performance scores: Karnofsky performance score was assessed in each patient by one observer. The EORTC QLQ C-30 questionnaire was completed by each patient and results analyzed according to the scoring manual (version 3).
Statistics
All analyses were performed with SPSS (version 11.5). Descriptive statistics were used for demographic, baseline, safety and efficacy variables. Arithmetic means of efficacy variables at baseline and 8 weeks were compared using Student's t test.
Results
Thirteen patients received the combination regimen. Patient baseline characteristics and flow through the study are summarized in ESM 2 and Fig. 1 , respectively. Patients were heavily pre-treated with surgery, chemotherapy and/or radiotherapy and all had end-stage, advanced disease (stage 4). Median age was 67 years and mean BMI was 22.3. Mean prior weight loss was 11 %, generally documented over the prior 5-7 months, though in some cases much more recently. Of the 13 patients enrolled, 9 completed at least 4 weeks and 7 completed the full 8-week course. Adherence to therapy was close to 100 %; out of 2,196 doses which could have been taken, only 24 were missed.
Six patients discontinued study treatment prior to completing 8 weeks. In two cases, this was clearly due to their underlying malignancy. In the other four, although the event precipitating withdrawal may have been caused by the study treatment, there was in each case a co-morbidity or malignant progression which was a more probable cause or at least a Of the seven patients who reached 8 weeks, six had a major response to treatment ( Table 2) . Major responders showed a high degree of consistency in magnitude of strength improvement between lower limb (knee extension) and upper limb (hand grip) and between left and right limbs. Increases in strength were highly concordant with increases in muscle size (ESM 3). Due to the small sample size, few increases reached statistical significance. The increase in mean quadriceps volume between baseline and 8 weeks was 6 % for the left limb (p = 0.012) and 4 % for the right limb (p = 0.004). The increases in mean IKES and LLEP were 17 and 12 %, respectively, for the left limb (p =0.078, 0.531) and 8 % for the right limb (p =0.389, 0.588). The increase in mean HGS was 16 % for the left limb (p =0.010) and 10 % for the right limb (p = 0.159). Lower limb muscle quality improved by 11 % for the left limb (p =0.250) and 5 % for the right limb (p =0.527).
The mean total body weight of the seven patients who completed treatment increased by 2.6 % from 58.7 kg at baseline to 60.2 kg at 8 weeks (p =0.379). Five of the seven patients increased their total body weight, from 1.8 to 14.2 %.
Average physical activity increased >1,000 steps per day between baseline and the end of treatment in 3/6 major responders. Average daily step count declined in the other three major responders, each of whom was, during the end-oftreatment assessment period, suffering from an intercurrent illness/morbidity which adversely affected their activity, one with a DVT, one with worsening ankle oedema and one with influenza. Global health status measured using the QLQ-C30 questionnaire was unchanged from baseline to end of treatment while the functional domains all showed a small but nonsignificant increase in mean score. For most of the symptom scales, mean scores fell slightly between baseline and week 8, indicating a trend towards symptomatic improvement. For lack of appetite, the improvement was marked (76.2 vs. 23.8; p =0.005).
Few adverse events were considered probably or possibly related to study medication (ESM 4) the commonest being tremor (eight reports in seven patients), peripheral oedema (three), tachycardia (two) and dyspepsia (two). For the patients who developed a tremor, this was mild (six patients) or moderate (one patient) and either resolved within the first 2 weeks (three patients) or persisted intermittently (four patients). One patient developed a supraventricular tachycardia 14 days after treatment (grade 3 adverse event) that was possibly drug related and resulted in withdrawal from the study. The patient had an undisclosed history of similar episodes prior to study entry. Fifteen SAEs were reported during the study, all judged unrelated to study medication, and in almost all cases due to progression of the underlying malignancy.
Discussion
The present study has demonstrated that the combination of formoterol fumarate and megestrol acetate is safe and well tolerated in frail patients with advanced cancer and cachexia. For those patients who reached evaluation at 8 weeks (7/13), a pre-defined overall major 'muscle response' was observed in 6/7. Thus, although there was the expected attrition of patients during the trial, the majority of those remaining on study had a major response for muscle mass and/or function. In this study, the experimental therapy was not randomized against an active or placebo control arm, thus interpretation of the changes observed in muscle mass or function can only be speculative. However, clinical experience and published data suggest that muscle loss in advanced cancer patients with cachexia is relentless, especially in the final year of life [15] and there is little evidence of spontaneous recovery. The 40 % attrition of patients by 8 weeks is comparable with previous studies in similar groups of frail patients with advanced disease and cachexia, in whom disease progression and co-morbidities are very common [16] . Even in this frail population, adverse drug reactions played little part in those discontinuations which did occur. The selectivity of formoterol for skeletal over heart muscle [13] may have helped in this regard. The oral use of less selective β 2 -agonists such as clenbuterol has been limited principally by cardiovascular side effects, a significant concern in an advanced cancer population, in around a quarter of whom significant cardiovascular co-morbidity can be expected. In this study, there were only two episodes of tachycardia, one of which resolved without leading to patient discontinuation. The other episode, in a patient with a prior undisclosed history of SVT, also resolved but the patient was withdrawn from the study as a precaution. Another adverse effect associated with β 2 -agonists, tremor, occurred frequently in this study but was generally mild, often relatively short-lived and did not directly cause any discontinuations. The dose of formoterol chosen for the study was the usual starting dose of formoterol for its respiratory indications. It remains to be seen whether a lower dose of formoterol would avoid these adverse effects while retaining adequate efficacy.
The mean change in muscle volume for the patients with a major response at 8 weeks was 6 and 4 % for left and right quadriceps, respectively, which is consistent with increases seen in both young and older healthy volunteers undergoing resistance exercise training over a similar period of time [17, 18] . Thus, the mean change observed in the major responders in the present study is physiologically significant. For those with a major response in this study, the proportional changes in muscle volume were generally matched or exceeded in percentage terms by increases in muscle strength. Such improvements in muscle function could result from increased muscle mass or may be related to the known effects of β 2 -agonists on muscle fibre type [19] . Clearly, one of the limitations of using MRI is that it does not measure muscle protein content.
It was not possible to determine whether the apparent gain in muscle mass in the 'muscle responders' was due to the formoterol alone or due to the combination with megestrol acetate. In a study of healthy elderly men given megestrol acetate alone (800 mg/day), thigh muscle cross-sectional area actually decreased by 4.5 % over a period of 3 months [20] . The induction of muscle atrophy by progestational agents has been ascribed to the suppression of circulating testosterone levels [21] . However, about 70 % of male patients with advanced cancer are already hypogonadal [22] and previous studies of progestational agents in cachectic cancer patients have suggested that lean body mass remains stable [23] .
One of the key physiological stimuli for protein synthesis in skeletal muscle is dietary protein intake. Anorexia and reduced protein and energy intake are key components of the cachexia syndrome [24] , and at baseline, this study population demonstrated marked lack of appetite. Progestational agents are powerful appetite stimulants and are known to increase food intake in weight-losing cancer patients [25] . We did not measure food intake but patient-reported lack of appetite improved significantly. The anabolic action of β 2 -adrenoreceptor agonists is maintained when substrate availability is reduced by food restriction in animal models [26] . Thus, in circumstances where megestrol is unable to restore normal food intake to normal, there may still be the potential for benefit from formoterol.
Improvements in both muscle mass and muscle function are likely to be a requirement for the regulatory approval of a new drug therapy for cancer cachexia. In addition, a clear improvement in clinical outcome, in terms of survival or quality of life, may also be required. Physical activity is one of the key domains of quality of life that may be altered by the successful treatment of cachexia. Previous large randomized trials in cancer cachexia have failed to show any clear benefit from progestational agents on quality of life in general and physical function in particular [25] . In this study, the average daily step count increased by over 1,000 steps per day in 3/6 major responders, suggesting that improvements in appendicular musculature can translate directly into clinically relevant improvements in physical functioning. However, physical activity may be sensitive to the patient's day-to-day clinical condition, which may confound results. For example, one patient was suffering from influenza at the time of posttreatment assessment and this was reflected in a dramatic decline in step count despite an underlying major muscle response. It is therefore suggested that continuous monitoring of physical activity throughout the treatment period would be preferable, in order to minimise the confounding effect of 'dips' in performance due to co-incidental illness or extraneous factors.
Conclusions
The present study has demonstrated that the combination of formoterol fumarate and megestrol acetate is safe and well tolerated in frail patients with advanced cancer and cachexia. For those patients who reached evaluation at 8 weeks (7/13), a pre-defined overall major response was observed in 6/7. These data support the further development of formoterol and megestrol as a treatment for cancer cachexia.
